[JS10] Cutting Edge of NanoDDS Technology Supporting New Modalities in Drug Discovery: Challenges in the Treatment of Intractable Diseases

Sun. Mar 31, 2024 9:45 AM - 11:45 AM [Room 303] Conference Center 303 (3F)

Organizer: Yoichi Negishi (Sch. Pharm., Tokyo Univ. Pharm. Life Sci.), Takanori Kanazawa (Grad. Sch. Bioｍed. Sci., Tokushima Univ.)

In recent years, the drug discovery research has been changing dramatically, and new drug development using new modalities such as antibody-drug conjugates, nucleic acid drugs, cell-based therapeutics, and regenerative medicine has become more active, focusing on disease areas where unmet medical needs are high. On the other hand, in order to achieve efficient delivery and introduction of these new modalities into target organs and tissues, it is important to apply nanoDDS technology that enables the control of pharmacokinetics in the body by avoiding foreign substance recognition mechanisms, overcoming in vivo barriers, and accommodating tissue-specific constructs related to the disease's pathophysiology. In this context, lipid nanoparticles and polymeric micelles have been developed so far, and recently, research and development of nanoDDS technology using extracellular vesicles like exosomes has rapidly advanced. In this symposium, we will introduce the cutting edge of nanoDDS research and development, which will lead to the development of new delivery mechanisms and therapeutic strategies. We would like to discuss strategies for the treatment of intractable diseases using nanoDDS technology that contributes new drug modalities by gaining a deeper understanding of overcoming and bypassing in vivo barriers, the biological environment, and defense mechanisms.

+Add all to schedule

オーガナイザー挨拶：根岸洋一（東京薬大薬） (9:45 AM - 9:50 AM)

9:50 AM - 10:12 AM

[JS10-1] Nucleic acid delivery to deeper regions of central nervous system by nose-to-brain nano-DDS for the treatment of brain and spinal cord diseases

○Takanori Kanazawa^1,2 (1. Grad. Sch. Bioｍed. Sci., Tokushima Univ., 2. DDS Res. Cent., Tokushima Univ.)

10:12 AM - 10:34 AM

[JS10-2] Development of nanoparticle-based drug delivery systems and cell therapies for the treatment of intractable diseases

○Tatsuya Fukuta^1,2, Mayumi Ikeda¹, Ninad Kumbhojkar², Samir Mitragotri² (1. Sch. Pharm. Sci., Wakayama Med. Univ., 2. Harvard SEAS)

10:34 AM - 10:56 AM

[JS10-3] Development of spleen-targeted delivery system by utilizing immune responses against nanoparticles

○Taro Shimizu^1,2,3,4, Tatsuhiro Ishida^4,5 (1. Inst. Microbial Dis., Osaka Univ., 2. Inst. Open Transdisciplinary Res., Osaka Univ., 3. Cent. Adv. Modalities and DDS, Osaka Univ., 4. Grad. Sch. of Pharm., Tokushima Univ., 5. DDS Res. Cent., Tokushima Univ.)

10:56 AM - 11:18 AM

[JS10-4] Ultrasound-responsive nanobubbles allowing the various modalities to pass through the biological barriers

○Yoko Endo-Takahashi¹, Yoichi Negishi¹ (1. Sch. Pharm., Tokyo Univ. Pharm. Life Sci.)

11:18 AM - 11:40 AM

[JS10-5] Old and new intraperitoneal administration for efficient drug delivery to peritoneal dissemination

○Hiroto Hatakeyama¹ (1. Grad. Sch. Pharm. Sci., Chiba Univ.)

総括：金沢貴憲^1,2（¹徳島大院医歯薬，²徳島大DDSセ） (11:40 AM - 11:45 AM)